- Lilly and Boehringer Ingelheim report results from EMPA-REG OUTCOME trial assessing Jardiance and placebo, both added to standard of care in adults with type 2 diabetes and established cardiovascular disease.
- Total cardiovascular events included 3P-MACE (a composite of non-fatal heart attack, non-fatal stroke and cardiovascular death), hospitalization for heart failure and all-cause hospitalization.
- Previously, Jardiance reduced the relative risk of 3P-MACE by 14%, driven by a 38% reduction in the relative risk of cardiovascular death.
- https://seekingalpha.com/news/3637472-lillys-jardiance-reduced-risk-of-cardiovascular-events-in-adults-type-2-diabetes
Wednesday, November 18, 2020
Lilly Jardiance reduced risk of cardiovascular events in adults with type 2 diabetes
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.